Research ArticleCLINICAL INVESTIGATIONS
Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol
Lanell M. Peterson, David A. Mankoff, Thomas Lawton, Kevin Yagle, Erin K. Schubert, Svetlana Stekhova, Allen Gown, Jeanne M. Link, Timothy Tewson and Kenneth A. Krohn
Journal of Nuclear Medicine March 2008, 49 (3) 367-374; DOI: https://doi.org/10.2967/jnumed.107.047506
Lanell M. Peterson
David A. Mankoff
Thomas Lawton
Kevin Yagle
Erin K. Schubert
Svetlana Stekhova
Allen Gown
Jeanne M. Link
Timothy Tewson
In this issue
Journal of Nuclear Medicine
Vol. 49, Issue 3
March 2008
Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol
Lanell M. Peterson, David A. Mankoff, Thomas Lawton, Kevin Yagle, Erin K. Schubert, Svetlana Stekhova, Allen Gown, Jeanne M. Link, Timothy Tewson, Kenneth A. Krohn
Journal of Nuclear Medicine Mar 2008, 49 (3) 367-374; DOI: 10.2967/jnumed.107.047506
Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol
Lanell M. Peterson, David A. Mankoff, Thomas Lawton, Kevin Yagle, Erin K. Schubert, Svetlana Stekhova, Allen Gown, Jeanne M. Link, Timothy Tewson, Kenneth A. Krohn
Journal of Nuclear Medicine Mar 2008, 49 (3) 367-374; DOI: 10.2967/jnumed.107.047506
Jump to section
Related Articles
Cited By...
- Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16{alpha}-18F-Fluoro-17{beta}-Fluoroestradiol
- Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology
- Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer
- 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer
- Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes
- Initial Studies with 11C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer
- Breast Cancer 18F-ISO-1 Uptake as a Marker of Proliferation Status
- 18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT
- 18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-{alpha} Mutations in Breast Cancer
- 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients
- Molecular Imaging in Cancer Drug Development
- Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial
- 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
- Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer
- A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer
- Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer
- 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications
- Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation
- Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer
- Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression
- Molecular Imaging of Biomarkers in Breast Cancer
- Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degrader
- Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using 16{alpha}-18F-Fluoro-17{beta}-Estradiol PET/CT
- Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer
- 18F-FES and 18F-FDG PET for Differential Diagnosis and Quantitative Evaluation of Mesenchymal Uterine Tumors: Correlation with Immunohistochemical Analysis
- Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer
- PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
- Novel insights on imaging sex hormone-dependent tumourigenesis in vivo
- Breast Cancer and Hormonal Stimulation: Is Glycolysis the First Sign of Response?
- Cancer-focused Molecular Imaging
- 18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis
- Imaging Tumor Phenotype: 1 Plus 1 Is More Than 2
- Molecular Imaging: 18F-FDG PET and a Whole Lot More
- The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions
- Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
- Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography
- Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11{beta}-Methoxy-16{alpha}-18F-Fluoroestradiol Using Serial Whole-Body PET/CT
- Tumor Receptor Imaging